{"id":"anlotinib-plus-pemetrexed","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":{"chemblId":"CHEMBL4303201","moleculeType":"Small molecule","molecularWeight":"407.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anlotinib is a multi-target tyrosine kinase inhibitor that suppresses VEGFR, FGFR, and other kinases involved in tumor blood vessel formation and growth. Pemetrexed is an antifolate agent that inhibits thymidylate synthase and other folate-dependent enzymes, disrupting nucleotide synthesis and inducing apoptosis. The combination leverages complementary mechanisms: antiangiogenic activity plus direct cytotoxic chemotherapy.","oneSentence":"Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:18.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC), likely advanced or metastatic stages"}]},"trialDetails":[{"nctId":"NCT04136535","phase":"PHASE2","title":"Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-11-18","conditions":"NSCLC Stage IV","enrollment":105},{"nctId":"NCT05188859","phase":"PHASE2","title":"First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-09-01","conditions":"Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced","enrollment":29},{"nctId":"NCT06475755","phase":"PHASE2","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-30","conditions":"Non-Small Cell Lung Cancer, Anti Angiogenesis","enrollment":178},{"nctId":"NCT03866980","phase":"PHASE3","title":"A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Akeso","startDate":"2018-11-27","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":164},{"nctId":"NCT06277674","phase":"PHASE2","title":"Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2023-11-02","conditions":"Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04012619","phase":"PHASE1","title":"Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"Sichuan University","startDate":"2019-04-30","conditions":"Non-squamous Non-small-cell Lung Cancer, Anlotinib","enrollment":8},{"nctId":"NCT05842018","phase":"PHASE2","title":"Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-01","conditions":"Non Small Cell Lung Cancer Recurrent","enrollment":30},{"nctId":"NCT05346952","phase":"PHASE3","title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-25","conditions":"Advanced Non-squamous Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT04958993","phase":"PHASE1, PHASE2","title":"A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-11-12","conditions":"Non-small Cell Lung Cancer","enrollment":7},{"nctId":"NCT04846452","phase":"PHASE2","title":"Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-01","conditions":"Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer","enrollment":40},{"nctId":"NCT04846634","phase":"PHASE2","title":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08","conditions":"Resectable Locally Advanced Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT04316351","phase":"PHASE2","title":"Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2020-04-01","conditions":"IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy","enrollment":60},{"nctId":"NCT04453423","phase":"PHASE2","title":"Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-07-01","conditions":"Non-squamous Non-small-cell Lung Cancer","enrollment":90},{"nctId":"NCT04439890","phase":"PHASE3","title":"A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-08-08","conditions":"Advanced Non-squamous Cell Non-small Cell Lung Cancer","enrollment":369},{"nctId":"NCT03790228","phase":"PHASE1","title":"Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-03-22","conditions":"Non-squamous Cell Non-Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT03706287","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2018-12-06","conditions":"Lung Cancer Metastatic","enrollment":62},{"nctId":"NCT04181372","phase":"PHASE2","title":"A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2019-12","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":50},{"nctId":"NCT04124731","phase":"PHASE2","title":"Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2019-10","conditions":"Carcinoma, Non-small Cell Lung Cancer","enrollment":98},{"nctId":"NCT03778138","phase":"PHASE2","title":"Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2019-01-01","conditions":"Non-squamous Cell Non-Small Cell Lung Cancer","enrollment":51},{"nctId":"NCT03768037","phase":"PHASE4","title":"Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2018-11-26","conditions":"Advanced Non-squamous NSCLC","enrollment":106},{"nctId":"NCT03671538","phase":"NA","title":"Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin","status":"UNKNOWN","sponsor":"Lingyu Luo","startDate":"2018-10-01","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":62},{"nctId":"NCT03636685","phase":"PHASE1, PHASE2","title":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-08-15","conditions":"NSCLC, Adenocarcinoma, Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT03628521","phase":"PHASE1","title":"First-line Combination Treatment Based on Anlotinib","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2018-07-20","conditions":"Lung Cancer, Advanced Stage","enrollment":80},{"nctId":"NCT03589950","phase":"PHASE2","title":"Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The First People's Hospital of Lianyungang","startDate":"2018-08-01","conditions":"Lung Neoplasms, Docetaxel, Pemetrexed","enrollment":60},{"nctId":"NCT03566576","phase":"NA","title":"Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2018-07-01","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anlotinib plus Pemetrexed","genericName":"Anlotinib plus Pemetrexed","companyName":"Henan Provincial People's Hospital","companyId":"henan-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib, a vascular endothelial growth factor receptor 2 inhibitor, is combined with Pemetrexed and Carboplatin as a first-line treatment for advanced non-squamous Non-Small Cell Lung Cancer. This combination is part of a clinical trial (NCT03790228) to evaluate its efficacy in treating patients with this condition.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}